Deep multi-instance learning model based on gadoxetic acid-enhanced MRI for predicting microvascular invasion of hepatocellular carcinoma: a multicenter, retrospective study

基于钆塞酸增强磁共振成像的深度多示例学习模型预测肝细胞癌微血管侵犯:一项多中心回顾性研究

阅读:1

Abstract

OBJECTIVE: Microvascular invasion (MVI) is of great significance for the individualized treatment of hepatocellular carcinoma (HCC) and preoperative noninvasive prediction of MVI is still an urgent clinical problem. To explore the effects of different regions of interest (ROI) and image input dimensions on the performance of deep learning (DL) models, and to select the best result to develop and validate a DL model for preoperative prediction of MVI. MATERIALS AND METHODS: A total of 206 patients with pathologically confirmed HCC from three hospitals were retrospectively enrolled and divided into training, internal validation and external test set. Based on hepatobiliary phase images (HBP) of gadoxetic acid-enhanced MRI, 2D DL, 3D DL and 2.5D deep multi-instance learning (MIL) models were established. The receiver operating characteristic curve (ROC) was used to evaluate the predictive efficacy of the above models. Based on the optimal performance model, the T1WI-FS and T2WI-FS images were preprocessed correspondingly, and a multimodal prediction model including three sequences was constructed. The ROC, and decision curve were used to visualize the predictive ability of the model. RESULTS: Compared with 2D DL and 3D DL models, the 2.5D DL model based on all axial images of ROI had the highest performance, with the AUC values of 0.802 (95% CI, 0.669-0.936) and 0.759 (95% CI, 0.643-0.875) in the validation and test sets. The AUCs of the multimodal MRI model were 0.954 (95% CI, 0.920-0.989) in the training set, 0.857 (95% CI, 0.736-0.978) in the validation set, and 0.788 (95% CI, 0.681-0.895) in the test set. CONCLUSION: The DL model that selects all axial slices of intratumor and peritumor as input shows robust capability in predicting MVI, which is expected to help clinical decision-making of individualized treatment for HCC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。